July 31 (Reuters) - Eli Lilly and Co LLY.N:
ELI LILLY: MOUNJARO SHOWED CARDIOVASCULAR PROTECTION IN HEAD-TO-HEAD TRIAL, REINFORCING BENEFIT IN PATIENTS WITH TYPE 2 DIABETES, HEART DISEASE
ELI LILLY: MOUNJARO MET PRIMARY OBJECTIVE OF NON-INFERIORITY VERSUS. TRULICITY WITH 8% LOWER RATE OF MACE-3 EVENTS
ELI LILLY: MOUNJARO WAS ASSOCIATED WITH 16% LOWER RATE OF ALL-CAUSE DEATH COMPARED TO TRULICITY